Group 1 - The core viewpoint highlights the recent surge in the stock prices of innovative pharmaceutical companies in China, with notable increases in companies such as Four Seasons Pharmaceutical, Hengrui Medicine, and WuXi AppTec [1] - Foreign investments have intensified in Chinese innovative drug companies, with significant share purchases by entities like the Government of Singapore Investment Corporation (GIC) and BlackRock [1] - GIC increased its stake in Hengrui Medicine by acquiring 40.22 million shares at an average price of 12.7133 HKD per share, raising its ownership from 1.62% to 6.37% [1] Group 2 - The domestic innovative drug sector has experienced rapid growth, with 83 licensing agreements reached this year, totaling approximately 84.53 billion USD, including upfront payments of 4.32 billion USD [2] - The upcoming World Conference on Lung Cancer (WCLC) from September 6-9, 2025, is expected to showcase 35 oral presentations by Chinese scholars, highlighting the clinical data of domestic new drugs [2] - There is optimism regarding the value recovery of core assets in the second half of the year, as noted by Zhongyou Securities [2]

Core Viewpoint - WuXi AppTec (02268) has announced a share placement agreement to raise approximately HKD 1.3 billion, primarily aimed at expanding its service capacity and production capabilities in bioconjugates and active pharmaceutical ingredients [1] Group 1: Share Placement Details - The company has signed a placement agreement with underwriters to fully underwrite up to 22.77 million shares at a price of HKD 58.85 per share, expecting net proceeds of about HKD 1.3 billion [1] - Approximately 90% of the raised funds will be allocated to enhance the group's service capacity and production capabilities, particularly in bioconjugates, active pharmaceutical ingredients, and clinical and commercial production [1] - The remaining 10% of the funds will be used for working capital and general corporate purposes [1] Group 2: Subscription Agreement - WuXi AppTec has also entered into a subscription agreement with its controlling shareholder, WuXi Biologics (02269), to issue 24.134 million subscription shares at the same price of HKD 58.85 per share, with net proceeds expected to be around HKD 1.4 billion [1] - Similar to the placement, about 90% of the subscription proceeds will be directed towards further expanding the group's service capacity and production capabilities, including bioconjugates and active pharmaceutical ingredients [1] - The remaining 10% will be allocated for the group's working capital needs and general corporate purposes [1]

Core Viewpoint - WuXi AppTec (02268) has announced a share placement agreement to raise approximately HKD 1.3 billion, primarily aimed at expanding its service capacity and production capabilities in bioconjugates and APIs [1] Group 1: Share Placement Details - The company signed a placement agreement to fully underwrite up to 22.77 million shares at a price of HKD 58.85 per share [1] - The expected net proceeds from this placement are approximately HKD 1.3 billion, with about 90% allocated for expanding service capacity and production, particularly in bioconjugates, APIs, and commercial production [1] - The remaining 10% of the funds will be used for working capital and general corporate purposes [1] Group 2: Subscription Agreement - WuXi AppTec has also entered into a subscription agreement with its controlling shareholder, WuXi Biologics (02269), to issue 24.134 million subscription shares at the same price of HKD 58.85 per share [1] - The net proceeds from this subscription are expected to be around HKD 1.4 billion, with a similar allocation of approximately 90% for expanding service capacity and production [1] - The remaining 10% will also be directed towards working capital needs and general corporate purposes [1]

Core Viewpoint - WuXi AppTec (02268.HK) has entered into a subscription agreement with WuXi Biologics (02269.HK) to issue and allocate 24.134 million shares at a subscription price of HKD 58.85 per share, raising approximately HKD 14.20 billion [1] Group 1 - The subscription price of HKD 58.85 represents a discount of about 4.00% compared to the last closing price of HKD 61.30 [1] - The total expected proceeds from the subscription are approximately HKD 14.20 billion, equivalent to about USD 1.82 billion [1] - The net proceeds from the subscription are expected to be around HKD 14.14 billion, or approximately USD 1.81 billion, with a net price per share of about HKD 58.61 [1] Group 2 - Approximately 90% of the net proceeds will be used to further expand the group's service capabilities and production capacity, including but not limited to clinical and commercial production capacity for antibody-drug conjugates, active pharmaceutical ingredients, and drugs [1] - About 10% of the net proceeds will be allocated for the group's working capital needs and general corporate purposes [1]

Core Viewpoint - WuXi AppTec (02268) has entered into a subscription agreement with its controlling shareholder WuXi Biologics (02269) to issue 24.134 million subscription shares at a price of HKD 58.85 per share, raising approximately HKD 1.42 billion [1] Group 1 - The net proceeds from the subscription are approximately HKD 1.414 billion [1] - About 90% of the proceeds will be used to further expand the group's service capabilities and production capacity, including but not limited to clinical and commercial production capacity for bioconjugated drugs, active pharmaceutical ingredients, and pharmaceuticals [1] - Approximately 10% of the proceeds will be allocated for the group's working capital needs and general corporate purposes [1] Group 2 - The subscriber is the controlling shareholder of the company, thus classified as a related party under the listing rules [1]

Core Viewpoint - WuXi AppTec announced a placement agreement with an underwriter to fully underwrite up to 22.277 million shares at a price of HKD 58.85 per share, aiming to raise approximately HKD 1.311 billion in total, with net proceeds of about HKD 1.301 billion [1] Fund Utilization - Approximately 90% of the raised funds will be used to expand the company's service capabilities and production capacity, particularly in the areas of antibody-drug conjugates, active pharmaceutical ingredients, and clinical and commercial production [1] - The remaining approximately 10% of the funds will be allocated for the company's working capital and general corporate purposes [1]

Core Viewpoint - WuXi AppTec (02268) announced a subscription agreement with WuXi Biologics (02269) to issue 24.134 million subscription shares at a price of HKD 58.85 per share, totaling approximately HKD 1.42 billion [1] Group 1 - The net proceeds from the subscription are approximately HKD 1.414 billion, with about 90% allocated for expanding the group's service capabilities and production capacity, including clinical and commercial production of bioconjugates, active pharmaceutical ingredients, and drugs [1] - Approximately 10% of the proceeds will be used for the group's working capital needs and general corporate purposes [1] - The subscriber is the controlling shareholder of the company, qualifying as a related party under the listing rules [1]

財務顧問 – 1 – 有關根據特別授權認購新股份的關連交易 於2025年9月3日（ 聯交所交易時段前 ），本公司與認購人訂立認購協議，據此， 本公司已有條件同意發行及配發而認購人已有條件同意認購24,134,000股認購股 份， 認購價 為每 股認 購股份 58.85 港 元（ 與 配售 價相同 ）， 總代 價約 為1,420.29 百 萬港元。認購股份將根據特別授權發行及配發。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的 任何其他司法管轄區內刊發或派發。 本公告僅作參考用途，並不構成收購、購買或認購證券的邀請或要約，亦並非擬 用作邀請提出任何相關要約或邀請。 本公告並不構成或組成在美國購買或認購證券的任何要約或招攬的一部份。本公 告所述證券並未且將不會根據1933年美國《證券法》（「美國《證券法》」）進行登記 ...

Core Viewpoint - WuXi AppTec (02268.HK) has announced a placement agreement with Morgan Stanley to issue up to 22.277 million shares at a price of HKD 58.85 per share, representing a discount of approximately 4.00% from the last closing price of HKD 61.30 [1] Group 1: Placement Details - The maximum number of shares to be placed represents approximately 1.85% of the existing issued share capital and about 1.82% of the enlarged issued share capital after the placement [1] - The total expected proceeds from the placement will be approximately HKD 1.311 billion (around USD 168 million), with net proceeds estimated at about HKD 1.301 billion (around USD 167 million) [1] Group 2: Use of Proceeds - Approximately 90% of the net proceeds will be used to further expand the group's service capabilities and production capacity, including clinical and commercial production capacity for bioconjugates, active pharmaceutical ingredients, and products [1] - About 10% of the net proceeds will be allocated for the group's working capital needs and general corporate purposes [1]

来源：格隆汇APP 格隆汇9月3日｜药明合联(2268.HK)在港交所公告，于2025年9月2日（联交所交易时段后），本公司与 配售代理订立配售协议，公司已有条件同意透过配售代理按悉数包销基准按配售价每股配售股份58.85 港元（较最新收盘价折价约4%）向不少于六名承配人配售最多22,277,000股配售股份。配售事项的最高 所得款项总额将约为13.11亿港元。配售股份将根据一般授权发行及配发。 ...